CiRA starts service offering HLA-typed iPS cell stocks, Dainippon Sumitomo first customer

Kyoto University’s CiRA has initiated a service based on human leukocyte-antigen (HLA)-typed iPS cell stocks. Appropriate HLA-types in tissue transplantation greatly reduces the risk of rejection. This time, CiRA has offered to Dainippon Sumitomo and its Helios joint venture to prepare HLA-typed retinal pigment epithelial cells (RPE cells) for clinical trials with appropriate patients, to be started in 2017.

CiRA website, Nikkei Biotech news release August 6, 2015

CiRA starts service offering HLA-typed iPS cell stocks, Dainippon Sumitomo first customer
Scroll to top